SeaStar Medical Holding Corp (ICU): Nasdaq/NYSE listing notice — SeaStar Medical receives Nasdaq delisting notice for failing Market Value Rule; hearing requested

SeaStar Medical Holding Corp

Nasdaq notified SeaStar on Dec 12, 2023, that it failed to regain compliance with the $35M market value requirement under Listing Rule 5550(b)(2).
Company will timely request a hearing before a Nasdaq Hearing Panel, which stays any delisting action pending the hearing.
Common stock (ICU) continues trading on Nasdaq Capital Market during the hearing process.
Prior deficiency letters were disclosed in June 2023 regarding the same market value non-compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

December 12, 2023, the Company received notification from the Staff that the Company had not regained compliance with the Market Value Rule (the “ Delisting Notice ”) or the alternative criteria. The Delisting Notice indicated that the Company’s common stock would be subject to delisting unless the Company timely requests a hearing before a Nasdaq Hearing Panel (the “ Panel ”). Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will stay any suspension or delisting action pending the hearing. Subject to the Company’s timely submission of a hearin

View on SEC.gov

Browse all listing & compliance notices →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0000950170-23-069889

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.